ATE237311T1 - Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung - Google Patents

Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Info

Publication number
ATE237311T1
ATE237311T1 AT95926111T AT95926111T ATE237311T1 AT E237311 T1 ATE237311 T1 AT E237311T1 AT 95926111 T AT95926111 T AT 95926111T AT 95926111 T AT95926111 T AT 95926111T AT E237311 T1 ATE237311 T1 AT E237311T1
Authority
AT
Austria
Prior art keywords
vinca alkaloid
tumor targeting
vesicles
increased effectiveness
liposome
Prior art date
Application number
AT95926111T
Other languages
English (en)
Inventor
Eric Forssen
Gerry W Cox
Denniss Hair
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE237311T1 publication Critical patent/ATE237311T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT95926111T 1994-06-27 1995-06-27 Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung ATE237311T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26605994A 1994-06-27 1994-06-27
US08/389,663 US5714163A (en) 1994-06-27 1995-02-16 Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
PCT/US1995/008037 WO1996000057A1 (en) 1994-06-27 1995-06-27 Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties

Publications (1)

Publication Number Publication Date
ATE237311T1 true ATE237311T1 (de) 2003-05-15

Family

ID=26951608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926111T ATE237311T1 (de) 1994-06-27 1995-06-27 Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Country Status (9)

Country Link
US (2) US5714163A (de)
EP (1) EP0734252B1 (de)
AT (1) ATE237311T1 (de)
AU (1) AU684209B2 (de)
CA (1) CA2191077C (de)
DE (1) DE69530368T2 (de)
DK (1) DK0734252T3 (de)
ES (1) ES2197919T3 (de)
WO (1) WO1996000057A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2000059473A1 (en) 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
US7244450B2 (en) * 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
EP1685843A1 (de) * 1999-06-30 2006-08-02 Ruey J. Dr. Yu Oligosaccharidealdonsäure und ihre topische Verabreichung
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
EP1229934B1 (de) 1999-10-01 2014-03-05 Immunogen, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
EP1372664A1 (de) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Verwendung von steroiden für die behandlung von blutzellenmangel
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
US20070026061A1 (en) * 2005-05-25 2007-02-01 Nahid Ali Liposomal formulation and use thereof
EP1932517A3 (de) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
PL387296A1 (pl) * 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
CA2891656C (en) 2012-11-20 2021-05-04 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198C (en) * 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
ES2068197T3 (es) * 1987-01-27 1995-04-16 Vestar Inc Vehiculo de liberacion a base de fosfolipidos para ingredientes activos insolubles en agua.
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
WO1990015595A1 (en) * 1989-06-22 1990-12-27 Vestar, Inc. Encapsulation process
US5322862A (en) * 1990-05-22 1994-06-21 Nippon Kayaku Kabushiki Kaisha Resin molding composition for preventing gnawing damage by animals
EP0661044A1 (de) * 1991-07-03 1995-07-05 NeXstar Pharmaceuticals, Inc. Arzneistoff enthaltende Liposomen
ES2078034T3 (es) * 1991-07-03 1995-12-01 Vestar Inc Tecnica de carga para preparar liposomas que contienen farmacos.
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties

Also Published As

Publication number Publication date
CA2191077C (en) 2008-02-05
DE69530368D1 (de) 2003-05-22
DK0734252T3 (da) 2003-07-21
AU2998495A (en) 1996-01-19
EP0734252B1 (de) 2003-04-16
US5888537A (en) 1999-03-30
AU684209B2 (en) 1997-12-04
WO1996000057A1 (en) 1996-01-04
CA2191077A1 (en) 1996-01-04
ES2197919T3 (es) 2004-01-16
DE69530368T2 (de) 2003-12-18
US5714163A (en) 1998-02-03
EP0734252A1 (de) 1996-10-02

Similar Documents

Publication Publication Date Title
ATE237311T1 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
DE69923181D1 (de) Temperatursensitive liposomale formulierung
AU2709495A (en) Sphingosomes for enhanced drug delivery
AU3922193A (en) Liposome encapsulated taxol and a method of using the same
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
GR1000074B (el) Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
AU4711296A (en) Method for loading lipid vesicles
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO2001039744A3 (en) Radiation sensitive liposomes
NZ503568A (en) Biphasic lipid vesicle composition for transdermal administration of an immunogen
AU4221400A (en) Fusogenic lipids and vesicles
IT1199967B (it) Liposomi contenenti interleucina,metodo per la loro preparazione e loro uso terapeutico nelle affezioni tumorali
CA2148074A1 (en) Cosmetic or pharmaceutical composition for topical use
ES2134846T3 (es) Formulacion de antibiotico y uso para infecciones resistentes a farmacos.
ATE226843T1 (de) Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
ES2152324T3 (es) Vesiculas lipidicas multilaminares bifasicas.
ATE260643T1 (de) System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform
WO2003018018A3 (en) Vinorelbine compositions and methods of use
DE3851842T2 (de) Wässrige bereitung von liposomenzusammensetzungen.
DK1360958T3 (da) Liposomformulering af clobetasolpropionat
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon
ES2130969A1 (es) Biomembranas para la encapsulacion extemporanea de tetracaina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0734252

Country of ref document: EP